

4/PRTS
WO 99/64607

PCT/FR99/01343

1

INDUSTRIAL PROCESS FOR PRODUCING HETEROLOGOUS PROTEINS
IN *E. COLI* AND STRAINS USEFUL FOR SAID PROCESS

The present invention relates to a novel
5 industrial process for producing heterologous proteins
in *E. coli*. While for certain heterologous proteins
with very high added value the cost price of the
process for preparing them remains a factor which is
negligible with compared to the purpose of the
10 heterologous protein (in the pharmaceutical domain in
particular), the development of the industrial
production of heterologous proteins of lower added
value in *E. coli* involves taking into account
production factors such as the necessity of having an
15 increased biomass and a very high content of
heterologous proteins produced for the lowest possible
cost, which cost should take account of the nature of
the media, of the energetic and reagent yield and of
the operating conditions. For industrial productions
20 using reaction volumes which can reach several dozens
of m³, the simplest possible media and operating
conditions will be sought. The present invention
consists of the selection of an *E. coli* strain suitable
for satisfying the conditions above, which are
25 essential for economically satisfactory industrial

WO 99/64607

PCT/FR99/01343

2

production of heterologous proteins, independently of the value of the protein produced.

The strains of *E. coli* most commonly used for molecular biology studies derive from the strain K12
5 (Swartz. 1996, In *Escherichia coli* and *Salmonella*, Cellular and Molecular Biology, 2nd edition, ASM Press Washington, pp. 1693-1711). Derivatives of *E. coli* B, such as BL21, are also used for producing proteins, because of their physiological properties. A table of
10 the strains most commonly used for producing recombinant proteins is given by Wingfield, 1997 (Current Protocols in Protein Science, Coligan et al. Ed. John Wiley & Sons, Inc. 5.0.1-5.0.3).

Many systems for expressing proteins in
15 bacterial hosts have been described (Makrides, 1996, Microbiol. Rev. 60:512-538; Current Opinions in Biotechnology, 1996, 7). An expression system consists of a promoter, of its regulator, of a ribosome binding site followed by a restriction site which allows the
20 insertion of the gene of interest, of a structure which can be used as a transcription terminator, optionally of genes the coexpression of which increases the quality of the protein of interest overexpressed, and of one or more vectors which make it possible to
25 introduce these combinations into the host.

WO 99/64607

PCT/FR99/01343

3

The promoter must have at least three properties in order to be used in a process for producing proteins (Makrides, 1996, mentioned above):

- it must be strong and cause the accumulation of the protein of interest, which can represent 10 to 50% of the total proteins of the host cell;
- it must be capable of being regulated so as to be able, as far as possible, to uncouple the biomass production phase from the protein production phase;
- it must be inducible (passage from a level of low transcriptional activity to a maximum level of transcriptional activity) using simple and inexpensive process conditions.

Many promoters have been described for expression in *E. coli* (Makrides, 1996, mentioned above; Weickert et al., 1996, Current Opinions in Biotechnology 7 : 494-499). Among the homologous promoters used for producing proteins in *E. coli*, mention may be made of the *lac*, *trp*, *lpp*, *phoA*, *recA*, *araBAD*, *proU*, *cst-1*, *tetA*, *cadA*, *nar*, *tac*, *trc*, *lpp-lac*, *Psyn* and *cspA* promoters. Among the heterologous promoters used for producing proteins in *E. coli*, mention may be made of the *PL*, *PL-9G-50*, *PR-PL*, *T7*, *λPL-PT7*, *T3-lac*, *T5-lac*, *T4 gene 32*, *nprM-lac*, *VHb* and *Protein A* promoters. A certain number of drawbacks are linked to these promoters. For some of

WO 99/64607

PCT/FR99/01343

4

them, mention may be made of the use of IPTG as the inducer molecule, the price of which can represent more than 14% of the cost of the medium. Others use regulation by temperature, which is difficult to
5 implement on the scale of a 100 m³ industrial fermenter.

The vectors most commonly used for expressing proteins in *E. coli* derive from the plasmid pBR322 (Swartz, 1996, mentioned above; Makrides, 1996, mentioned above). They are present in cells at a
10 certain copy number, which is determined by the interaction of two RNAs encoded by the plasmid, RNAI and RNAII (Polisky, 1988, Cell 55 : 929-932). The interaction of RNAI with RNAII inhibits the maturation of RNAII into a form required for the initiation of the
15 replication of the plasmid. This interaction is modulated by the protein ROP, the gene of which is present on pBR322 but not on certain derivatives, such as the pUC-type plasmids (Lin-Chao and Cohen, 1991, Cell 65 : 1233-1242). With regard to regulation of the
20 number of copies of the expression plasmid in *E. coli*, several strategies are mentioned (Swartz, 1996, mentioned above; Makrides, 1996, mentioned above).
It will be appreciated in particular that a high number of copies of expression plasmid leads to a high level
25 of messenger RNAs of the desired protein, but can be

WO 99/64607

PCT/FR99/01343

5

detrimental to the metabolism of the host cell (Bailey, 1993, Adv. Biochem. Eng. Biotechnol. 48 : 29-52).

The stability of the expression plasmids is an important criterion, all the more so given that industrial fermentations tend not to use antibiotics in the fermenters. Several strategies have been developed to stabilize expression plasmids, including the cloning of the *cer* locus of the natural plasmid ColE1. This locus has been characterized (Leung et al., 1985, DNA 4 : 351-355) and its insertion into multicopy plasmids has been described as having a beneficial effect on the stability of these plasmids (Summers and Sherratt, 1984, Cell 36 : 1097-1103).

While the strains and expression systems above make it possible to obtain good heterologous protein production yields, their use remains limited to the production of heterologous proteins with very high added value for which the cost price of the production system (bacterial strain, culture medium and conditions, raw materials) is minimal compared with the value of the protein produced. As examples of such proteins with very high added value, there are more particularly the heterologous proteins intended for pharmaceutical use, such as for example human growth factor, human alpha consensus interferon, human

WO 99/64607

PCT/FR99/01343

6

interleukins 1β , $\alpha 1$ and 2, human leukocyte interferon, human parathyroid hormone, human insulin, human serum albumin or human proapolipoprotein A-1 (Lee, 1996, Trends in Biotechnol. 14:98-105; Latta et al., 1987, Bio/Technology 5 : 1309-1313).

However, for the mass production of chemical intermediates (Lee, 1997, Nature Biotech. 15 : 17-18) or for the production of enzymes for industrial use, in particular of the catalysts required for producing chemical compounds, the cost price of the production system becomes a dominant factor to be taken into consideration in order to evaluate the technical advantage of said system.

For the production of heterologous proteins in bacteria, the productivity of the culture system employed can be significantly increased by using high cell density culturing strategies (S. Makrides, 1996, mentioned above; Wingfield, 1997, mentioned above).

Among these is the fed-batch strategy (Jung et al., 1988, Ann. Inst. Pasteur/Microbiol. 139 : 129-146; Kleman et al., 1996, Appl. Environ. Microbiol. 62 : 3502-3507; Lee, 1996, mentioned above; Bauer and White, 1976, Biotechnol. Bioeng. 18 : 839-846). This strategy, combined with the use of a P_{trp} promoter, has made it possible to achieve significant productivities: 55 g of

WO 99/64607

PCT/FR99/01343

7

dry weight per liter, and 2.2 g of heterologous protein per liter (Jung et al., 1988, mentioned above). Routine productions of 35 to 50 g of dry weight per liter are reported (Wingfield, 1997, mentioned above).

5 However, the strains and systems above do not make it possible to obtain culture densities which are sufficient for the industrial production of heterologous proteins for which the value (cost price) must be negligible compared to their purpose (in
10 particular for the preparation of biological catalysts).

The present invention lies in the selection of a specific strain of *E. coli*, which is suitable for the industrial production of heterologous proteins. The
15 strain which is useful for the process according to the invention is an *E. coli* strain W, more particularly the strain W referenced at the ATCC under the number 9637.

This strain W (ATCC 9637) is well known, and described in many publications (Davies & Mingioli,
20 1950, J. Bact., 60: 17-28; Doy and Brown, 1965, Biochim. Biophys. Acta, 104: 377-389; Brown and Doy, 1966, Biochim. Biophys. Acta, 118: 157-172; Wilson & Holden, 1969, J. Biol. Chem., 244: 2737-2742; Wilson & Holden, 1969, J. Biol. Chem., 244: 2743-2749; White,
25 1976, J. Gen. Microbiol., 96: 51-62; Shaw & Duncombe,

WO 99/64607

PCT/FR99/01343

8

1963, Analyst 88: 694-701; Br. Pharmacopoeia, 1993, 2:
A164-A169; Huang et al., US 3,088,880; Hamsher et al.,
US 3,905,868; Takahashi et al., US 3,945,888; Huang et
al., US 3,239,427; Burkholder, 1951, Science, 114:
5 459-460; Prieto et al., 1996, J. Bact., 178: 11-120;
Lee 1996, mentioned above; Lee & Chang, 1995, Can.
J. Microbiol, 41: 207-215; Lee et al., 1994,
Biotechnol. Bioeng., 44: 1337-1347; Lee & Chang, 1993,
Biotechnology Letters. 15: 971-974; Bauer and White,
10 1976, mentioned above; Bauer and Shiloach, 1974,
Biotechnol. Bioeng 16: 933-941; Gleiser and Bauer,
1981, Biotechnol. Bioeng., 23: 1015-1021; Lee and
Chang, 1995,, Advances in Biochem. Engine./Biotech.
52: 27-58). The strain W (ATCC9637) has thus been used
15 for the production of 3-polyhydroxybutyric acid (PHA)
after introduction of a plasmid carrying the operon of
Alcaligenes eutrophus encoding enzymes involved in the
PHA biosynthesis (Lee and Chang, 1993, mentioned above;
Lee and Chang, 1995, mentioned above; Lee et al.,
20 1994).

The strain W has also been used in high cell
density cultures (Bauer and White, 1976, mentioned
above; Bauer and Shiloach, 1974, mentioned above;
Gleiser and Bauer, 1981, mentioned above; Lee and
25 Chang, 1993, mentioned above; Lee et al., 1997,

WO 99/64607

PCT/FR99/01343

9

Biotechnology Techniques 11: 59-62). Biomasses of 125 g of dry weight per liter have thus been obtained (Lee and Chang, 1993, mentioned above) using sucrose as a carbon source.

5 However, this strain has never been described for the production of recombinant proteins.

Furthermore, in combining a plasmid carrying the operon of *Alcaligenes eutrophus* encoding enzymes involved in PHA biosynthesis and a strategy of culturing the
10 corresponding recombinant strain W at high cell density, Lee and Chang (1993, mentioned above) obtained worse PHA productivity than with a strain XL1-Blue derived from the strain K12 (Lee and Chang, 1995, mentioned above; Lee, 1996, mentioned above).

15 The present invention relates, therefore, to an industrial process for preparing heterologous proteins in *E. coli*, in which *E. coli* bacteria modified with a suitable system for expressing heterologous proteins are seeded and cultured in a suitable culture
20 medium, characterized in that the strain of *E. coli* is an *E. coli* strain W. More preferably, the strain W is the strain W deposited at the ATCC under the number 9637.

According to one particular embodiment of the
25 invention, the strain W is a derivative of the strain

WO 99/64607

PCT/FR99/01343

10

deposited at the ATCC under the number 9637, obtained by clonal selection or genetic manipulation.

According to the invention, the term "industrial process" is intended to mean any process in which the bacterial culture volume is greater than the usual culture volume employed in research laboratories. Generally, the term "industrial process" is intended to mean any process for which the culture volume is greater than 2 liters, preferably greater than or equal to 10 liters, more preferably greater than or equal to 20 liters, even more preferably greater than or equal to 50 liters. The process according to the invention is particularly suitable for culture volumes from several dozens of m³ up to more than 100 m³.

The suitable culture medium is a culture medium which is suitable for the production of a high density of biomass and a high content of heterologous proteins produced. Several types of medium (defined, complex and semidefined) can be used for high cell density culturing (Lee, 1996, mentioned above). While the known media of the prior art, and in particular semidefined media, make it possible to accumulate good reproducibility of the composition of the medium and good productivity of the culture (Lee, 1996, mentioned above), the development of such a medium requires,

WO 99/64607

PCT/FR99/01343

11

however, empirical optimization for taking into account the economic constraints set out previously (Lee, 1996, mentioned above).

According to one preferential embodiment of the invention, the culture medium comprises sucrose as the main carbon source. According to the invention, the expression "main carbon source" is intended to mean that the sucrose represents at least 50% by weight of the total weight of the carbon sources of the culture medium, more preferably at least 75% by weight, even more preferably at least 85% by weight. According to a more preferential embodiment of the invention, the culture medium comprises substantially only sucrose as a carbon source. It is understood that, for the process according to the invention, the culture medium can comprise suitable additives so as to increase the overall yield of the invention. These additives can have the ancillary function of behaving as a carbon source to the bacterial culture. However, these additives will not be considered as a carbon source for the purpose of the present invention if the *E. coli* W bacteria used in the process according to the invention cannot grow on said additives as the sole carbon source.

WO 99/64607

PCT/FR99/01343

12

Advantageously, the amount of sucrose in the culture medium of the process according to the invention is between 0.1 and 300 g/l at the start of culturing, (before seeding), preferably between 0.5 and 200 g/l. It is understood that, since the sucrose constitutes the main carbon source of the medium according to the invention, the amount of sucrose will be decreasing during the process. In general, at the end of the reaction, the amount of sucrose in the culture medium at the end of the reaction is between 0 and 10 g/l.

According to one advantageous embodiment of the invention, the suitable culture medium also comprises a supplementary organic nitrogen source. This supplementary organic nitrogen source can consist of all organic nitrogen sources known to a person skilled in the art. Preferably, the supplementary organic nitrogen source consists of protein extracts. These protein extracts have more preferably the following composition: (in g amino acids per 100 g of product)

B alanine between 10 and 4, aspartic ^{acid} ~~lactate~~ between 11 and 4, glycine between 22 and 2.5 and lysine between 7 and 4. Meat or potato peptones or proteins satisfy such a profile, is/are particularly preferred for the

WO 99/64607

PCT/FR99/01343

13

particularly the derivatives of potato proteins are preferred.

According to the invention, the expression "suitable system for expressing heterologous proteins" is intended to mean any expression system comprising regulation elements suitable for the expression of heterologous proteins in *E. coli* W. These regulation elements comprise in particular promoters, ribosome binding sites and transcription terminators.

Advantageously, the expression system comprises a P_{trp} promoter. The P_{trp} promoter has been used in several examples (EP Application 0 198 745; CIP Application No. 08/194,588; Application WO 97/04083; Latta et al., 1987, Bio/Technology 5: 1309-1314; Denèfle et al., 1987, Gene 56: 61-70). In particular, Latta et al. (1990, DNA Cell. Biol. 9: 129-137) have conducted a detailed study on the influence of regulatory sequences upstream of the promoter, and of tandem-duplicated promoter sequences, and on the influence of the coexpression of the TrpR repressor. Their reference construct, pXL534, was used as a basis for the construction of pXL642 (CIP Application No. 08/194,588), used in the examples which illustrate the present invention. Preferably, the P_{trp} promoter

WO 99/64607

PCT/FR99/01343

14

comprises the nucleic acid sequence represented by
sequence identifier No. 1 (SEQ ID NO 1).

According to one embodiment of the invention,
in order to improve the level of expression of the
5 heterologous protein, a coexpression of the molecular
chaperones of *E. coli* GroESL (review by Makrides, 1996,
mentioned above) is carried out. The increase in the
intracellular concentration of the GroESL proteins
makes it possible, in effect, to assist the folding of
10 the recombinant protein and thus improve the level of
active protein (Weicker et al., 1996, Curr. Opin.
Biotechnol. 7: 494-499). The genes whose coexpression
promotes the expression of the heterologous protein
according to the invention, and its quality, are
15 included in the expression system according to the
invention.

According to the invention, the term
"heterologous protein" is intended to mean any protein
produced by the process according to the invention
20 which is not naturally found in *E. coli* W, in the
suitable expression system according to the invention.
It can be a protein of nonbacterial origin, for example
of animal, in particular human, or plant origin, or a
protein of bacterial origin which is not naturally
25 produced by *E. coli* W, or a protein of bacterial origin

WO 99/64607

PCT/FR99/01343

15

naturally produced by a bacterium other than *E. coli* W or a protein naturally produced by *E. coli* W, the expression of which is controlled by regulation elements different from those of the expression system according to the invention, or finally, a protein which
5 derives from the preceding ones after modification of certain elements of its primary structure.

Of course, the process according to the invention applies to any protein of interest the
10 production of which requires a great accumulation of proteins before either extracting them and purifying them, totally or partially, or using them in a mixture with the biomass which will have made it possible to produce them. It is the case, for example, of enzymes
15 which are useful for the biocatalysis of chemical reactions, and which can be used without a prior isolation and purification procedure, or also of enzymes which are used in the host bacterium in the process of growing, for the biotransformation of
20 chemical compounds.

Advantageously, the heterologous protein is an enzyme produced in industrial amounts for a subsequent use as a chemical reaction catalyst. According to one particular embodiment of the
25 invention, the enzyme is a nitrilase, advantageously a

WO 99/64607

PCT/FR99/01343

16

nitrilase of *Alcaligenes faecalis* (ATCC8750) described in patent application WO 98/18941 or a nitrilase of *Comamonas testosteroni* sp. described in CIP application No. 08/194,588, or an amidase such as those described
5 in applications WO 97/04083, EP 433 117 and EP 488 916, or a hydroxyphenylpyruvate dioxygenase described in application WO 96/38567.

The present invention also relates to an *E. coli* strain W as defined above, characterized in that
10 it comprises a system for expressing heterologous proteins, in which the promoter is the *P_{trp}* promoter defined above.

The examples hereinbelow make it possible to illustrate the present invention without, however,
15 seeking to limit the scope thereof.

The appended figures 1 to 3 represent maps of plasmids used in the various examples.

Figure 1 represents the map of the plasmid pRPA-BCAT41. The sites in brackets are sites which were
20 eliminated during cloning. *P_{trp}*: tryptophan promoter; *nitB*: nitrilase gene; *TrnB*: transcription terminators; end ROP: end of the gene encoding the ROP protein (Chambers et al., 1988, Gene 68: 139-149); ORI: origin of replication; RNAI/II: RNAs involved in replication

WO 99/64607

PCT/FR99/01343

17

(Chambers et al., mentioned above); Tc: tetracyclin resistance gene.

β

Figure 2 ^{represents} ~~represents~~ 1 map of the plasmid pRPA-BCAT127. The sites between brackets have been eliminated during cloning. Ptrp: tryptophan promoter; nitB: nitrilase gene; TrrnB: transcription terminators; ORI: origin of replication; RNAI^{*}/II: mutated RNAs involved in replication; Cm: chloramphenicol resistance gene; cer: cer locus.

Figure 3 represents the map of the plasmid pRPA-BCAT103. The sites between brackets have been eliminated during cloning. Sm/Sp: streptomycin and spectinomycin resistance gene; parABCDE: par locus (Roberts and Helinski, 1992, J. Bacteriol. 174: 8119-8132); rep, mob, D20 and ori: regions involved in the replication and transfer of the plasmid (Scholtz et al., 1989, Gene 75: 271-288; Frey et al., 1992, Gene 113: 101-106).

Figure 4 represents the map of the plasmid pRPA-BCAT126. Ptrp: tryptophan promoter; nitB: nitrilase gene; TrrnB: transcription terminators; ORI: origin of replication; RNAI^{*}/II: mutated RNAs involved in replication; Tc^r: tetracycline resistance gene; cer: cer locus.

WO 99/64607

PCT/FR99/01343

18

Figure 5 represents the map of the plasmid pRPA-BCAT143. Sm/Sp: streptomycin and spectinomycin resistance gene; rep, mob, and ori: regions involved in the replication and transfer of the plasmid (Scholtz et al., 1989, Gene 75: 271-288; Frey et al., 1992, Gene 113: 101-106); delta relates to the name of the deletion described in the text.

The techniques used are conventional molecular biology and microbiology techniques known to a person skilled in the art and described, for example, by Ausubel et al., 1987 (Current Protocols in Molecular Biology, John Wiley and Sons, New York), Maniatis et al., 1982, (Molecular Cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), Coligan et al., 1997 (Current Protocols in Protein Science, John Wiley & Sons, Inc).

Example 1: Construction of the expression plasmids pBCAT29 and pBCAT41.

B
The 1.27 kb fragment ^{counting} containing the P_{trp} promoter, the ribosome binding site of the λ phage cII gene (RBScII) and the nitrilase gene of *Alcaligenes faecalis* ATCC8750 (*nitB*) was extracted from the plasmid pRPA6BCAT6 (application FR 96/13077) using the EcoRI and XbaI restriction enzymes, so as to be cloned into the vector pXL642 (described in CIP application

WO 99/64607

PCT/FR99/01343

19

No. 08/194,588) opened with the same restriction enzymes. The resulting plasmid, pRPA-BCAT15, was opened with the *Stu*I and *Bsm*I enzymes, and the 4.3 kb fragment was ligated with the purified 136 bp *Stu*I-*Bsm*I fragment of pRPA-BCAT4 (application FR 96/13077) so as to produce the plasmid pRPA-BCAT19. The partial sequencing of pRPA-BCAT19 confirmed the replacement of the codon of the Asp279 residue of the nitrilase with the codon of an Asn279 residue. The 1.2 kb *Eco*RI-*Xba*I fragment of pRPA-BCAT19 containing the *P_{trp}::RBScII::nitB* fusion was then cloned into the vector pRPA-BCAT28 opened with the same enzymes, so as to produce the 6.2 kb plasmid pRPA-BCAT29. The vector pRPA-BCAT28 was obtained by ligating the 3.9 kb *Ssp*I-*Sca*I fragment of pXL642 (CIP application No. 08/194,588) with the 2.1 kb *Sma*I fragment of pHP45 Ω Tc (Fellay et al., 1987, Gene 52: 147-154) in order to replace the ampicillin resistance marker with the tetracycline resistance marker. In destroying the *Nde*I site close to the origin of replication of the plasmid pRPA-BCAT29 by partial *Nde*I digestion and the action of *E. coli* Polymerase I (Klenow Fragment), a plasmid pRPA-BCAT41 was obtained, the map of which is represented in Figure 1. The sequence of the expression cassette is represented by sequence identifier No. 2 (SEQ ID NO 2).

REPLACEMENT SHEET (RULE 26)

WO 99/64607

PCT/FR99/01343

20

Example 2: Expression of the nitrilase of *A. faecalis* ATCC8750 in "batch" *E. coli* K12, BL21 and W.

The plasmids pRPA-BCAT29 and pXL2035 (Levy-Schill et al., 1995, Gene 161: 15-20) were introduced into the strains DH5 α (CLONECH. Product reference C1021-1), BL21 (Novagen, product reference 69386-1) and W (ATCC9637) of *E. coli* by conventional electroporation. Expression cultures were prepared as described in Example 5 of application FR 96/13077, reducing the preculture time to 8 hours and fixing the expression time at 16 hours. The biomasses after expression were estimated according to the optical density of the cultures, read at 660 nm (OD660), using the following equation: biomass in gram of dry weight per liter of culture = OD660 \times 0.35. The measurements of nitrilase activity of the cultures were carried out as described in application FR 96/13077. For each strain, two clones were analyzed and for each clone, the experiment was repeated. Table 1 contains, for each strain, the mean of the data obtained in the four experiments.

Table 1: Biomass and activities of the strains harboring the plasmids pRPA-BCAT29 and pXL2035

WO 99/64607

PCT/FR99/01343

21

STRAINS	BIOMASS (g/l)	ACTIVITY (U)	PRODUCTIVITY (P)
DH5 α	0.15	10.4	1.6
BL21	0.37	6.3	2.4
W	0.65	7.00	4.5

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture.

5 These data show that the strain W of *E. coli* (ATCC9637) is more effective at expressing the nitrilase NitB.

Example 3: Construction of pBCAT43.

10 The polyamide hydrolase gene of *Comamonas acidovorans* N12 described in application WO 97/04083 (pamII) was cloned into the vector pBCAT41. This polyamide hydrolase gene was amplified by PCR in the form of a 1.26 kb DNA fragment, while introducing, in the PCR primers, the EcoRI and NcoI restriction sites in the 5' position of the gene and the XbaI restriction site in the 3' position. This fragment was then treated successively with the EcoRI enzyme and Mung Bean nuclease. After extraction of the proteins with phenol-chloroform-isoamyl alcohol, the treatment was continued
15 with an XbaI digestion. Similarly, the vector pRPA-
20

WO 99/64607

PCT/FR99/01343

22

BCAT41 was opened with the NdeI enzyme, and then treated with Mung Bean nuclease. After extraction of the proteins with phenol-chloroform-isoamyl alcohol, the treatment was continued with an XbaI digestion. After ligation of these two samples, the plasmid pRPA-BCAT43 was obtained: it contains the P_{trp} promoter and the RBS_{ScII} binding site separated from the translation start codon of the *pamII* gene by the sequence: AATACTTACACC.

10 **Example 4: Expression of the polyamidase PamII in "batch" *E. coli* DH5 α , BL21 and W.**

The plasmid pRPA-BCAT43 was introduced into the strains DH5 α , L21 and W of *E. coli* by conventional electroporation. Expression cultures were prepared as described in Example 2 above and varying the expression time from 14 to 24 hours. The biomasses after expression were estimated as in example 2 above. The measurements of polyamide hydrolase activity of the cultures were carried out as described in application WO 97/04083, with the following modifications:


- the cells were permeabilized with toluene by resuspending the cell pellets in a 100 mM tris-HCl, 5 mM EDTA, pH8, 1% toluene buffer so as to have a dry cell concentration of approximately 5 g/l; after vigorous shaking, the suspension is incubated for one

WO 99/64607

PCT/FR99/01343

23

hour at 4°C and then centrifuged, and finally, the pellets of permeabilized cells are taken up in a 100 mM, pH7, phosphate buffer.

- the hydrolysis activity was measured on the AB
 - 5 oligomer (one molecule of adipic acid condensed to one molecule of hexamethylenediamine) present at 2.5 g/l in the reaction medium containing 0.1 M potassium phosphate buffer at pH 7, and incubated at 30°C with stirring:
 - 10 - 100 microliter samples are taken at regular intervals while adding to them the same volume of 0.2 N NaOH;
 - the samples are analyzed by HPLC after ten-fold dilution in a solution of 50 mM H₃PO₄.
 - 15 For each strain, from 1 to 24 clones were analyzed and for each clone, one to seven independent experiments were conducted. Table 2 contains, for each strain, the mean of the data obtained.
- Table 2:** Biomass and activities of the strains
- 20 harboring the plasmid *pRPA-BCAT43*
- 

WO 99/64607

PCT/FR99/01343

24

STRAINS	NB CULTURES	ACTIVITY (U)	PRODUCTIVITY (P)
DH5a	11	0.77	0.3
BL21	3	1.4	1.8
W	24	2.1	2.6

ABBREVIATIONS: NB: number; U: g of AB hydrolyzed per hour and per g of dry weight; P: g of AB hydrolyzed per hour and per liter of culture.

These data show that the strain W (ATCC9637) of *E. coli* is more effective for expressing the PamII polyamidase.

Example 5: Construction and characterization of the plasmid pBCAT41-531.

The plasmid pRPA-BCAT41 underwent a mutagenesis step carried out with hydroxylamine as described in Miller 1992 (Mutagenesis. A short course in bacterial genetics. "A laboratory manual and handbook for *E. coli* and related bacteria", Cold Spring Harbor Laboratory Press, Unit 4, pp. 81-212) and Humphreys et al., 1976 (Mol. Gen. Genet. 145: 101-108). Five micrograms of plasmid DNA purified on a cesium chloride gradient were incubated for 20 minutes at 80°C in a 50 mM sodium phosphate buffer, pH 6, containing 0.5 mM EDTA and 0.4 M NH₂OH. After the addition of an identical volume of 50 mM sodium phosphate buffer,

WO 99/64607

PCT/FR99/01343

25

pH 6, containing 0.5 mM EDTA, the reaction mixture was dialyzed against a large excess of 10 mM Tris-HCl buffer, pH 7.5, containing 1 mM EDTA and 100 mM NaCl. The plasmid DNA was then recovered by precipitation and
5 approximately 20 ng of DNA was introduced by electroporation into the strain DH5 α harboring the plasmid pXL2035. Among the transformants obtained, one clone was selected because the productivity of the culture was 3 times higher than that of a culture of
10 the strain DH5 α (pRPA-BCAT41, pXL2035). The plasmid pRPA-BCAT41-531 that it was harboring was extracted and reintroduced into a new DH5 α host harboring the plasmid pXL2035. Three clones were then analyzed under the conditions described in example 2, comparing them with
15 3 DH5 α clones (pRPA-BCAT41, pXL2035), and the results are given in table in Table 3.

Table 3: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41, pRPA-BCAT41-531 and pXL2035

WO 99/64607

PCT/FR99/01343

26

Strains	Biomass (g/l)	Activity (U)	Productivity (P)
DH5 α (pRPA-BCAT41, pXL2035)	0.21	12	2.5
DH5 α (pRPA-BCAT41- 531, pXL2035)	0.63	12	7.5

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture.

5 These results indicate that the improvement in the productivity of the cultures is correlated with the presence of the plasmid pRPA-BCAT41-531.

 The 1.27 kb EcoRI-XbaI fragment containing the $P_{trp}::nitB$ fusion was extracted from the plasmid pRPA-BCAT41 in order to be cloned in place of the one contained in pRPA-BCAT41-531. The resulting plasmid, pRPA-BCAT86, was introduced into the strain DH5a (pXL2035) and 3 transformants were studied under conditions similar to those described above. The results are given in Table 4.

Table 4: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41, pRPA-BCAT41-531, pRPA-BCAT86 and pXL2035

WO 99/64607

PCT/FR99/01343

27

Strains	Biomass (g/l)	Activity (U)	Productivity (P)
DH5 α (pRPA-BCAT41, pXL2035)	0.20	13.8	2.7
DH5 α (pRPA-BCAT41- 531, pXL2035)	0.68	11.0	7.4
DH5 α (pRPA-BCAT86, pXL2035)	0.69	11.9	8.1

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture.

5 The results show that the improvement in the productivity of the cultures harboring pRPA-BCAT41-531 is not due to an improvement in the specific activity of the strain, and that this improvement is not caused by a mutation in the fragment carrying the P_{trp} promoter
10 and the *nitB* gene.

Example 6: Characterization of a mutation carried by the plasmid pBCAT41-531 responsible for the improvement in productivity of the cultures of strains
15 **expressing nitrilase.**

The analysis of the amount of protein produced by the strains of example 5, by polyacrylamide

WO 99/64607

PCT/FR99/01343

28

gel electrophoresis in the presence of SDS, showed that all these constructs led to levels of nitrilase polypeptide synthesis which were comparable among the strains described in this example. On the other hand, preparations of plasmid DNA of pRPA-bCAT41 and pRPA-BCAT41-531 prepared from equivalent amounts of biomass demonstrated that the plasmid pRPA-BCAT41-531 is present at lower number of copies than its parent pRPA-BCAT41. The sequencing of the 994 bp region of pRPA-BCAT41-531, which stretches from the Tth111I site and covers the origin of replication of the plasmid, revealed two differences with respect to the sequence of the corresponding region of pBR322 (GeneBank #J01749, name: SYNpBR322). By referring to the numbering given in the sequence J01749 (0 is the middle of the unique EcoRI site), we found that an insertion of an A had taken place after base 2319, and that the C of position 3039 is replaced with a T, in pRPA-BCAT41-531. The first difference can be attributed to an error during the action of the Klenow polymerase which was used to destroy one of the NdeI sites of pRPA-BCAT29, and is located in a region which is not described as playing a role in the replication of pBR322 (Chambers et al., 1988, Gene 68: 139-149). The second error corresponds to a transition, a characteristic effect of

WO 99/64607

PCT/FR99/01343

29

hydroxylamine on DNA (Drake and Baltz, 1976, Annu. Rev. Biochem. 45: 11-37), and is located at the second nucleotide of the region transcribed into RNA I involved in the replication of pBR322 (Chambers *et al.*,
5 mentioned above). It is the latter mutation which is responsible for the lower number of copies of pRPA-BCAT41-531 in DH5 α and which is responsible for the better nitrilase productivity of the cultures of the strain DH5 α (pRPA-BCAT41-531, pXL2035).

10

Example 7: Expression of the nitrilase of *A. faecalis* ATCC 8750 in "fed-batch" (semicontinuous culture) *E. coli* BL21 and *E. coli* W.

The plasmids pRPa-BCAT41-531 and pXL2035 were
15 introduced by electroporation into the strains BL21 (reference mentioned above) and W (ATCC9637) so as to give the RPA-BIOCAT594 [BL21 (pRPA-BCAT41-531, pXL2035)] and RPA-BIOCAT714 [W (pRPA-BCAT41-531, pXL2035)] strains, respectively. The recombinants
20 *E. coli* BIOCAT 594 and *E. coli* BIOCAT 714 were cultured in 3.5 liter fermenters containing 2 liters of medium with the following composition:

WO 99/64607

PCT/FR99/01343

30

Compound	Concentration in g/l
KH_2PO_4	8
K_2HPO_4	6.3
$(\text{NH}_4)_2\text{SO}_4$	0.75
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	2.5
Iron sulfate	0.04
$\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$	0.05
Manganese sulfate	0.01
Cobalt chloride	0.004
Zinc sulfate	0.002
Sodium molybdate	0.002
Copper chloride	0.002
Boric acid	0.0005
Citrate [lacuna].H ₂ O	1.7
Glucose monohydrate	95
L-tryptophan	0.1
Meat peptone	5
Yeast extract	3

The pH is maintained at 7.0 by adding aqueous ammonia. The oxygen saturation is maintained at 20% by adding air in a proportion of 1 volume/volume of medium/minute and by stirring. The glucose is introduced at the start at a final concentration of 2 g/l. After having been totally consumed, it is

REPLACEMENT SHEET (RULE 26)

WO 99/64607

PCT/FR99/01343

31

introduced continuously from a stock solution with the following composition: 700 g/l glucose; 19.6 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$. The rate of addition is 2.2 g of glucose/h.l of medium.

5 After fermentation for 24 hours, the medium is recovered and centrifuged, and the dry weight is estimated in g/l. The enzymatic activity is measured following a protocol given in patent WO 96/09403. It is expressed in kilos of ammonium 3-hydroxybutanoate formed
10 per hour and per kilo of dry cells.

Strain	Final biomass	Final activity	Yield on glucose
BIOCAT 594 (BL21)	27 g/l	13	23%
BIOCAT 714 (W)	40 g/l	17	40%

In this example, it appears clearly that the nitrilase is expressed much better in E. coli W than in
15 E. coli BL21, and that the recombinant E. coli W BIOCAT 714 grows much better than the recombinant E. coli BL21 BIOCAT 594.

Example 8: Influence of the organic nitrogen
20 **source of animal origin.**

WO 99/64607

PCT/FR99/01343

32

The E. coli strain W BIOCAT 714 is cultured in a 3.5 liter fermenter containing 2 liters of medium with the following composition:

Compound	Concentration in the medium in g/l
K ₂ HPO ₄	8
(NH ₄) ₂ SO ₄	0.75
MgSO ₄ ·7H ₂ O	2.5
Iron sulfate	0.04
CaCl ₂ ·2H ₂ O	0.04
Manganese sulfate	0.026
Cobalt chloride	0.004
Zinc sulfate	0.013
Sodium molybdate	0.001
Copper chloride	0.001
Boric acid	0.00025
AlCl ₃	0.00125
Citrate [lacuna]·H ₂ O	1.7
Glucose monohydrate	95
L-tryptophan	0.1
Yeast extract	3

5

The pH is maintained at 7.0 by adding aqueous ammonia. The oxygen saturation is maintained at 20% by

REPLACEMENT SHEET (RULE 26)

WO 99/64607

PCT/FR99/01343

33

adding air in a proportion of 1 volume/volume of medium/minute and by stirring. The glucose is introduced at the start at a final concentration of 2 g/l. After having been totally consumed, it is

5 introduced continuously from a stock solution with the following composition: 700 g/l glucose; 19.6 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$. The rate of addition is 2.2 g of glucose/h.l of medium.

An organic nitrogen source of animal origin

10 is added to this medium.

Organic nitrogen source of animal origin	Final biomass	Final activity	Yield on glucose
None	30	2	40%
2.5 g/l of meat peptone	33	12	40%
5 g/l of meat peptone	40	25	45%
5 g/l of casein	35	20	43%

The use of an increasing concentration of organic nitrogen of animal origin significantly

15 increases the specific activity of the cells.

WO 99/64607

PCT/FR99/01343

34

Example 9: Influence of the organic nitrogen of plant origin.

The culture conditions are identical to those of example 8. In this example, organic nitrogen of
5 plant origin is added.

Organic nitrogen source of animal origin	Final biomass	Final activity	Yield on glucose
None	30	2	40%
5 g/l of soybean peptone	31	4	40%
5 g/l of wheat peptone	32	5	40%
7.5 g/l of sodium hydrolysate of potato protein (Alburex SP; Roquette)	35	17	43%

The addition of plant organic nitrogen does not give identical results depending on the origin.

10 Surprisingly, the addition of potato protein gives as good a result as the organic nitrogen of animal origin.

WO 99/64607

PCT/FR99/01343

35

Example 10: Influence of the carbon source.

The E. coli strain W BIOCAT 714 is cultured in a 3.5 liter fermenter containing 2 liters of medium with the following composition:

Compound	Concentration in the medium in g/l
Corn-steep LAB2218 (Roquette)	40
Yeast extract	3
MgSO ₄ ·7H ₂ O	2.5

The pH is maintained at 7.0 by adding aqueous ammonia. The oxygen saturation is maintained at 20% by adding air in a proportion of 1 volume/volume of medium/minute and by stirring. The carbon source is introduced at the start at a final concentration of 2 g/l. After having been totally consumed, it is introduced continuously from a stock solution with the following composition: 700 g/l carbon source; 19.6 g/l MgSO₄·7H₂O. The rate of addition is 2.2 g of glucose or of sucrose/h.l of medium.

The carbon source is varied in this example.

WO 99/64607

PCT/FR99/01343

36

Carbon source	Final biomass	Final activity	Yield on carbon
Glucose monohydrate 90 g/l	38	11	45%
"Syrup zero" (EUROSUCRE) 90 g/l	38	17	45%

In this example, it is observed that the use of sucrose ("syrup zero") as a carbon source significantly increases the specific activity of the
5 cells.

Example 11: Construction of a plasmid for coexpression of the TrpR regulator

A 434 bp DNA fragment which carries the *trpR*
10 gene and its promoter was extracted from the plasmid pRPG9 (Gunsalus and Yanofsky, 1980, Proc. Natl. Aca. Sci. USA 77: 7117-7121) using the AatII and StuI restriction enzymes. This fragment was cloned into the plasmid pSL301 (Brosius, 1989, DNA 8: 759-777) by
15 ligating it to the approximately 3.1 kb AatII-StuI fragment, so as to give the plasmid pRPA-BCAT30. The *trpR* gene and its promoter were then extracted from pRPA-BCAT30 in the form of a 475 bp EcoRI-NotI fragment in order to be cloned into the plasmid pXL2035 in place

WO 99/64607

PCT/FR99/01343

37

of a 240 bp EcoRI-NotI fragment. The resulting plasmid, pRPA-BCAT34, is therefore a derivative of pKT230 which allows the expression of the GroESL chaperones and of the TrpR regulator.

5

Example 12: Influence of the coexpression of GroESL and of TrpR.

The plasmid pRPA-BCAT34 was introduced by electroporation into the strains DH5 α (pRPA-BCAT29),
 10 BL21 (pRPA-BCAT29) and W (pRPA-BCAT29). Expression cultures of various strains were prepared as described in example 2, and the results are given in Table 5.

Table 5: Biomass and activities of the strains
 15 harboring combinations the plasmids pRPA-BCAT29, pXL2035 and pRPA-BCAT34

Combinations	pRPA-BCAT29		pRPA-BCAT29 pXL2035		pRPA-BCAT29 pRPA-BCAT34	
	U	P	U	P	U	P
DH5-alpha	0.37	0.16	10.4	1.6	2.0	0.7
BL21	0	0.0	6.4	2.4	5.6	2.0
W	1.7	0.96	7.0	4.5	8.9	6.5

WO 99/64607

PCT/FR99/01343

38

ABBREVIATIONS: U: activity, kg of HMTBA formed per hour and per kg of dry weight; P: productivity, kg of HMTBA formed per hour and per liter of culture.

5 The results show that the coexpression of GroESL makes it possible to increase the productivity of the cultures whatever the strain under consideration, by improving the specific activity of the cultures. This effect is correlated with an
10 increase in the solubility of the nitrilase polypeptide, as shown by an analysis of the proteins by electrophoresis as described in application FR 96/13077. The effect of the coexpression of the TrpR regulator is variable according to the strains, but
15 makes it possible, in W, to improve the productivity of the cultures.

Example 13: Influence of the presence of a cer locus on pRPA-BCAT41

20 The 382 bp HpaII fragment containing the cer locus of the plasmid ColE1 (Leung et al., 1985, DNA 4: 351-355) was cloned into the replicative form of the M13mp7 phage at one of the 2 AccI sites. The construct obtained then made it possible to extract, with the
25 EcoRI enzyme, an approximately 430 bp fragment

WO 99/64607

PCT/FR99/01343

39

containing the *cer* locus, which was cloned into
 pRPA-BCAT41 at the *EcoRI* site, thereby producing the
 plasmid pRPA-BCAT66. This plasmid was introduced by
 electroporation into the strain W harboring the plasmid
 5 pRPA-BCAT34. Expression cultures of various strains
 were prepared as described in example 2, extending the
 duration of the expression cultures to 24 hours and
 studying three clones of each strain in a sole
 experiment. The mean results are given in Table 6.

10

Table 6: Biomass and activities of the strains
 harboring the plasmids pRPA-BCAT41, pRPA-BCAT66 and
 pRPA-BCAT34

Strains	Biomass (g/l)	Activity (U)	Productivity (P)
W (pRPA-BCAT41, pRPA-BCAT34)	2.1	6.9	14.5
DH5 α (pRPA-BCAT66, pRPA-BCAT34)	1.8	10.0	18.0

15 ABBREVIATIONS: g/l: gram of dry weight per liter of
 culture; U: kg of HMTBA formed per hour and per kg of
 dry weight; P: kg of HMTBA formed per [lacuna]

WO 99/64607

PCT/FR99/01343

40

These results show that adding the cer locus to the plasmid for expression of the nitrilase leads to an improvement in the productivity of the cultures.

5 **Example 14: Construction of the plasmid**

pRPA-BCAT127

After elimination of the unique NdeI site of the plasmid pRPA-BCAT30 by digestion and formation of blunt ends with polymerase I (Klenow fragment), the
10 trpR gene was extracted from this latter plasmid in the form of an approximately 300 bp fragment prepared by treatment with the AatII enzyme followed by the action of polymerase I (Klenow fragment), and then, after inactivation of the reaction mixture, by digestion with
15 the SacII enzyme. This fragment was cloned into the pRPA-BCAT66 plasmid after opening this plasmid with Tth111 followed by treatment with polymerase I Klenow fragment) and, after inactivation, with SacII. The plasmid pRPA-BCAT82 was thus obtained. Its origin of
20 replication was replaced with that of the plasmid pRPA-BCAT41-531 by replacing the approximately 1.12 kb Bst1107I-Eam1105I fragment. The construct selected during this cloning, the plasmid pRPA-BCAT99, has an artefact which is in the form of a deletion of one
25 nucleotide at the Eam1105I site, transforming this site

WO 99/64607

PCT/FR99/01343

41

into a unique PshAI site. The resistance marker of the plasmid pRPA-BCAT99 was then changed by cloning, between the AatII and PshAI sites, an approximately 1.07 kb AatII-PshAI fragment prepared after PCR amplification of the gene encoding chloramphenicol resistance from the matrix pACYC184 (New England Biolabs #401-M), using the primers Cm1 and Cm2, the sequence of which is:

Cm1 : 5'-CCCCCGACAGCTGTCTTGCTTTCGAATTTCTGCC

10 Cm2 : 5'-TTGACGTCAGTAGCTGAACAGGAGGG

The plasmid thus obtained was called pRPA-BCAT123. It was then modified by eliminating the *trpR* gene in the form of an approximately 0.525 kb SacI-Bst1107I fragment, and reclosing the plasmid after forming blunt ends with the Pfu polymerase (15 minutes at 75°C in the buffer recommended by the manufacturer Stratagène, and in the presence of 0.2 mM of deoxynucleotides). The plasmid thus obtained is the plasmid pRPA-BCAT127, the map of which is represented schematically in Figure 2.

20

Example 15: Construction of the plasmids pRPA-BCAT98 and pRPA-BCAT103.

The plasmid pRPA-BCAT37, described in application FR 96/13077, was modified by replacing the approximately 3.2 kb SfiI-ScaI fragment with the

25

WO 99/64607

PCT/FR99/01343

42

approximately 2.42 kb SfiI-ScaI fragment of the plasmid RSF101D20 (Frey *et al.*, 1992, Gene 113: 101-106). This fragment contains a deletion in the 5' portion of the gene encoding the RepB primase, and reduces the frequency of transfer of the plasmid by 6 logs (Frey *et al.*, mentioned above). The plasmid thus obtained, pRPA-BCAT98, has several advantages: the loss of its mobilization functions makes it comply with the rules of industrial biosafety while at the same time retaining its properties of replication in Gram-negative bacteria.

The *par* locus (Gerlitz *et al.*, 1990, J. Bacteriol 172: 6194-6203) was then cloned on pRPA-BCAT98 as follows. The approximately 2.3 kb SphI-BamHI fragment of pGMA28 (Gerlitz *et al.*, mentioned above) was first cloned into the vector pUC18, thereby allowing its extraction in the form of a HindIII-EcoRI fragment so as to clone it into the vector pMTL22 (Chambers *et al.*, 1988, Gene 68: 139-49). The HindIII site was then destroyed by HindIII digestion and Klenow treatment. An approximately 2.38 kb fragment was then extracted with the PstI and BglII enzymes so as to be cloned into the vector pXL2426 at the PstI and BamHI sites and to produce the vector pXL2572. The vector pXL2426 originates from the replacement of the 2.38 kb

WO 99/64607

PCT/FR99/01343

43

SfiI-EcoRV fragment of pXL2391 (application FR 96/13077) with the 1.47 kb SfiI-EcoRV fragment of RSF1010D20. The cloning on the plasmid pXL2572, at the NdeI and BamHI sites, of an approximately 0.960 bp
5 NdeI-BamHI fragment of pRR71 (Weinstein et al., 1992, J. Bacteriol. 174: 7486-7489) made it possible to reconstitute the *par* locus as a whole on the plasmid pXL2573. This locus was then extracted from pXL2573 in the form of a 2.6 kb EcoRI-blunt end (after treatment
10 with PstI and Klenow) fragment in order to be cloned on the plasmid pRPA-BCAT98 opened with EcoRI and SacI, the latter end having been treated with the Pfu polymerase. The resulting plasmid was called pRPA-BCAT103 and its map is represented schematically in Figure 3.

15

Example 16: Use of the plasmids pRPA-BCAT98, pRPA-BCAT103 and pRPA-BCAT127 for expressing the nitrilase in W.

The plasmids pRPA-BCAT127, pRPA-BCAT98, pRPA-
20 BCAT103, pXL2035 and pXL2231 (application FR 96/13077) were introduced into the strain W of *E. coli* by electroporation, and expression cultures were prepared under the conditions described in example 2, using the following antibiotics: 12 µg/ml tetracycline for
25 pXL2231, 50 µg/ml kanamycin for pXL2035, 100 µg/ml

WO 99/64607

PCT/FR99/01343

44

streptomycin for pRPA-BCAT98 and pRPA-BCAT103, and 20 µg/ml chloramphenicol for pRPA-BCAT127. For each combination of plasmids, two to three clones were analyzed, and the mean results are given in Table 7.

5

Table 7: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41-531, pRPA-BCAT127, pRPA-BCAT98, pRPA-BCAT103, pXL2035 and pXL2231

Combination	Biomass (g/l)	Activity (U)	Productivity (P)
pBCAT127/pXL2231	1.43	4.9	7
pBCAT127/pBCAT103	1.75	7	12
pBCAT127/pBCAT98	1.72	11.2	19
pBCAT127/pXL2035	1.70	7.2	12
pBCAT41-531/pXL2035	1.36	5.9	8

10 ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture

The combinations pRPA-BCAT127/pRPA-BCAT98 and
15 pRPA-BCAT127/pRPA-BCAT103 allow an at least equivalent productivity to be obtained, using plasmids which are in conformity with the European criteria for biosafety.

WO 99/64607

PCT/FR99/01343

45

Example 17: Construction of the plasmid**pRPA-BCAT126**

The resistance marker of the plasmid pRPA-BCAT99 described in example 14 was changed as follows. The vector was opened with the PshAI and AatII enzymes and then treated with the Pfu polymerase (5 min at 75°C in the buffer recommended by the manufacturer Stratagène, and in the presence of 0.2 mM of deoxynucleotides), and the approximately 3.95 kb fragment was extracted from an agarose gel using the Quiaex kit (Quiagen) [other systems for recovering DNA can also be used, in particular those of chromatographic type]. It was ligated according to a conventional process with the 1.32 kb HindIII-BsmI fragment extracted from the plasmid pBR322 (New England Biolabs, ref 303-3S), and then treated as above with the Pfu polymerase. Among the plasmids obtained, the plasmid containing the insert carrying the tetracyclin resistance gene oriented in the same direction of transcription as the cassette for expressing the nitrilase was named pRPA-BCAT111. This plasmid was then opened with the NsiI and BstZ17I enzymes and then treated with the Pfu polymerase, and religated in order to eliminate the 0.47 kb fragment carrying the *trpR*

WO 99/64607

PCT/FR99/01343

46

gene. The plasmid obtained was named pRPA-BCAT126, the map of which is represented in Figure 4,

Example 18: Construction of the plasmid

5 pRPA-BCAT143

The plasmid pRPA-BCAT98 described in example 15 was opened with the SfiI and ScaI enzymes in order to replace the 2.42 kb fragment carrying the deletion in the 5' portion of the gene encoding the RepB primase with the 2.96 kb SfiI-ScaI fragment extracted from the plasmid RSF1010Δ18 carrying a 267 bp in-frame deletion in the 5' portion of the *repB* gene (Frey et al., 1992, Gene 113: 101-106). The deletion introduced on pRPA-BCAT143 decreases the frequency of transfer of the plasmid to 10^{-6} (Frey et al., 1992, Gene 113: 101-106) and makes it comply with the demands of the rules of biosafety. Unlike the plasmid pRPA6BCAT98 described above, this novel plasmid conserves a copy number close to the unmodified plasmid pXL2035 (Lévy-Schill et al., 1995, Gene 161: 15-20). It is represented in Figure 2.

Example 19: Use of the plasmids pRPA-BCAT126 and pRPA-BCAT143 for expressing the nitrilase in W

The plasmids pRPA-BCAT126, pRPA-BCAT127 (described above), pRPA-BCAT143, pRPA-BCAT98 and

WO 99/64607

PCT/FR99/01343

47

pXL2035 were introduced into the strain W of *E. coli* by electroporation, and expression cultures were prepared under the conditions described in example 2, using the following antibiotics: 12 µg/ml tetracycline for

5 pRPA-BCAT41-531 and pRPA-BCAT126, 50 µg/ml kanamycin for pXL2035, 100 µg/ml streptomycin for pRPA-BCAT98 and pRPA-BCAT143, and 20 µg/ml chloramphenicol for pRPA-BCAT127. For each combination of plasmids, two to three clones were analyzed, and the mean results are given in

10 Table 8.

Table 8: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41-531, pRPA-BCAT126, pRPA-BCAT127, pRPA-BCAT98, pRPA-BCAT143 and pXL2035

15

Combination	Biomass (g/l)	Activity (U)	Productivity (P)
pBCAT41-531/pXL2035	2.3	9.5	22
pBCAT41-531/pBCAT143	2.5	8.9	22
pBCAT126/pXL2035	2.2	9.8	21
pBCAT126/pBCAT98	1.3	3.5	4.5
pBCAT126/pBCAT143	2.5	8.1	20
pBCAT127/pBCAT143	2.8	7.1	20

WO 99/64607

PCT/FR99/01343

48

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture

- 5 Unlike the plasmid pBCAT98, the combinations of the plasmid pRPA-BCAT143 with one of the plasmids pRPA-BCAT41-531, pRPA-BCAT127 or pRPA-BCAT126 make it possible to conserve the productivity of the cultures prepared with the strains harboring the plasmid
- 10 pXL2035.